Rigor Reviewed

Rigor-Reviewed Manuscript

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.

Name: Αlpha¹ Rigor Record — Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
Item: Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
Rating: 39
Author: Αlpha¹

van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Williamson E, Pugh J, Manning G, Brown S, Burnett S, Hall E

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 1 critical, 3 high issues for “Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic−1★
IntegrityIntegrity concern ×2−1★
StatisticsStatistic did not reproduce−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: moderateReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced7 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Reported statistics do not recomputeRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions4

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Significance claim flips when recomputedRecomputed
Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Critical findings

• Recomputed 8 tests: 6 consistent, 2 inconsistent (1 change significance at p<.05); 1 recomputed directly from the reported test statistics, 7 via agent-written checks.

This is a well-conducted phase III randomized controlled trial with rigorous design, clear ethical approvals, and thorough reporting of biological variables and key resources. The main weaknesses are the lack of a specific data availability statement and the absence of a reporting guideline statement. A critical statistical verification finding shows that the reported non-inferiority p-value (0.004) is inconsistent with the recomputed value (0.145), which could affect the interpretation of the primary endpoint.

Both reviewers agreed on study type (interventional) and on all dimensions except statistical analysis, where the deterministic verification component overrode their pass. The statistics verification covered only 8 tests with test statistics or CIs; other p-values (e.g., threshold-only) were not machine-verified. The citation check found no retracted or unresolved references. The integrity check flagged only minor terminology inconsistencies.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 8 tests: 6 consistent, 2 inconsistent (1 change significance at p<.05); 1 recomputed directly from the reported test statistics, 7 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies on hypofractionation and SBRT, and the rationale for testing non-inferiority is clearly linked to the potential benefits of SBRT. The limitations of prior research are implicitly addressed by the trial design, though not explicitly discussed in the introduction.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 2]

“Previous studies have confirmed non-inferiority for moderately hypofractionated radiotherapy compared with conventionally fractionated radiotherapy, and moderate hypofractionation has been established as a standard-of-care option.”

direct quote[Introduction, paragraph 3]

“Stereotactic body radiotherapy (SBRT) builds on these developments to allow ultra-hypofractionated radiotherapy to be delivered with precision.”